By 2030, the cell and gene therapy market is projected to be worth £76.03bn, and logistics is essential in realising the ...

US President Donald Trump’s One Big Beautiful Bill Act (H.R. 1) has narrowly passed after US Vice President JD Vance broke a 50-50 deadlock in the US Senate.

Merck KGaA has concluded the previously announced acquisition of SpringWorks Therapeutics for an enterprise value of €3bn ($3.4bn).

Analysis shows Gilead’s recently approved drug for HIV prevention, Yeztugo, has the potential to transform the PrEP sector in the US.

Sanofi is to invest up to $25m in Adagene, which will enable the latter to fund its R&D efforts, including clinical development of muzastotug.

Jazz Pharmaceuticals has received conditional marketing authorisation from the European Commission for Ziihera for biliary tract cancer.

With its blockbuster Trikafta set to lose patent protection within the decade, Vertex is strengthening its cystic fibrosis portfolio.

Uruguay’s MSP has tasked a working group and a proposal has been created by the Faculty of Chemistry at the University of Uruguay.

Proposals for drug exclusivities and feeble measures to combat drug shortages are unlikely to boost innovation, say some ...

As the pharma sector braces for sector-specific tariffs from President Trump, what could the impact look like on supply ...

AbbVie gains control of an in vivo CAR-T therapy that could overcome limitations with currently approved autologous ...